CAS
ANIP icon

Coppell Advisory Solutions’s ANI Pharmaceuticals ANIP Stock Holding History

Coppell Advisory Solutions’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-599
Closed -$32.5K – 402
2024
Q4 		$32.5K Hold
599
– – ﹤0.01% 717
2024
Q3 		$35.2K Hold
599
– – 0.01% 668
2024
Q2 		$38.1K Buy
+599
New +$38.9K 0.01% 564
2023
Q4 		$30.6K Buy
+599
New +$33K 0.01% 617
2023
Q3 		– Sell
-820
Closed -$43.9K – 1217
2023
Q2 		$43.9K Buy
+820
New +$36.3K 0.01% 425

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Coppell Advisory Solutions's ANIP Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of ANI Pharmaceuticals (ANIP) in Q1 2025, closing a stake of 599 shares — an estimated $32.5K sold.

Coppell Advisory Solutions first reported a position in ANIP in Q2 2023 and held it in 5 quarters. The position peaked at $43.9K in Q2 2023. 230 funds tracked by Wall St. Rank hold ANIP as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining ANI Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 599 ANI Pharmaceuticals shares in Q1 2025, an estimated $32.5K.
  • Coppell Advisory Solutions first reported a position in ANI Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Coppell Advisory Solutions's ANI Pharmaceuticals position peaked at $43.9K in Q2 2023.
  • 230 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.